Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 MK-7240 in Moderately to Severely Active Ulcerative Colitis
jRCT2031230563Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of tulisokibart in autoimmune colitis (9 arms), sponsored by Merck & Co. Primary endpoints: Clinical remission per Modified Mayo Score at Week 12 (Study 1 and Study 2) and Clinical remission per Modified Mayo Score at Week 52 (Study 1). Started Mar 2024; status: active, not recruiting.
02
Drugs
tulisokibart
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2031230563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230563.